Immatics

Immatics is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer.

Business Model:

Revenue: $39.4M

Employees: 201-500

Detailed Immatics Information

Geographic Data

Immatics headquarters map

Address: Paul-Ehrlich-Str. 15

City: Tuebingen

State: baden-württemberg

Zip: 72076

Country: DE

Financial Info

Stage:

post ipo equity

Raised Last:

$104M

Raised Total:

$446M

Metrics

2,196,740Website Global Rank

8,824Website Monthly Traffic

Twitter Followers

Description

Immatics is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer.

Contact Phone:

Contact Email:

Immatics went public on 7/2/2020 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
7/2/2020

Ticker Symbol:
IMTX

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2014 Series D $0 AT Impf
dievini Hopp Biotech Holding
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
2/2007 Series B 7 $52.1M 3i Group
DH Capital
KfW
NTEC
OH Beteiligungen
Swisscom Ventures
Wellington Partners
3i Group
DH Capital
KfW
NTEC
OH Beteiligungen
Swisscom Ventures
Wellington Partners
9/2010 Series C 4 $71.2M AT Impf
dievini Hopp Biotech Holding
MIG Capital
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
MIG Capital
Wellington Partners
1/2017 Series E 2 $30M Amgen
Grazia Equity
Amgen
Amgen
Grazia Equity
9/2019 Venture Round 1 $75M Celgene
Celgene
10/2022 Post-IPO Equity $0 683 CAPITAL
Armistice Capital
Dellora Investments
EcoR1 Capital
Nantahala Capital Management
Perceptive Advisors
Rock Springs Capital
RTW Investments
Samsara BioCapital
SilverArc Capital
Sofinnova Investments
Wellington Management
683 CAPITAL
Armistice Capital
Dellora Investments
EcoR1 Capital
Nantahala Capital Management
Perceptive Advisors
Rock Springs Capital
RTW Investments
Samsara BioCapital
SilverArc Capital
Sofinnova Investments
Wellington Management
3/2020 Post-IPO Equity $0 AT Impf
dievini Hopp Biotech Holding
Perceptive Advisors
Redmile Group
RTW Investments LLC
Sphera Funds Management
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Perceptive Advisors
Redmile Group
RTW Investments LLC
Sphera Funds Management
Wellington Partners
10/2022 Post-IPO Equity $110M Armistice Capital
Dellora Investments
EcoR1 Capital
Nantahala Capital
Perceptive Advisors
Rock Springs Capital
RTW Investments
Samsara BioCapital
SilverArc Capital
Sofinnova Investments
Wellington Management
10/2013 Series D 3 $16.2M AT Impf
dievini Hopp Biotech Holding
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
10/2017 Series E 4 $58M Amgen
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
Amgen
Amgen
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
2/2004 Series A $0 3i Group
Wellington Partners
Merifin Capital
VINCI CAPITAL
L-Bank
Grazia Equity
EMBL Ventures
3i Group
Wellington Partners
Merifin Capital
VINCI CAPITAL
L-Bank
Grazia Equity
EMBL Ventures
7/2020 PIPE $104M Perceptive Advisors
4/2020 IPO -
4/2020 IPO -
3/2020 Post-IPO Equity 7 $104M AT Impf
dievini Hopp Biotech Holding
Perceptive Advisors
Redmile Group
RTW Investments LLC
Sphera Funds Management
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Perceptive Advisors
Redmile Group
RTW Investments LLC
Sphera Funds Management
Wellington Partners
7/2014 Series D 3 $29.8M AT Impf
dievini Hopp Biotech Holding
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
10/2013 Series D 3 $16.2M AT Impf
dievini Hopp Biotech Holding
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
Wellington Partners
9/2010 Series C 4 $71.2M AT Impf
dievini Hopp Biotech Holding
MIG
Wellington Partners
AT Impf
dievini Hopp Biotech Holding
MIG
Wellington Partners
2/2007 Series B 7 $52.1M 3i Group
DH Capital
KfW
NTEC
OH Beteiligungen
Swisscom Ventures
Wellington Partners
3i Group
DH Capital
KfW
NTEC
OH Beteiligungen
Swisscom Ventures
Wellington Partners
2/2004 Series A 7 $9.9M 3i Group
Wellington Partners
3i Group
Wellington Partners
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research